DAR determination using third generation conjugation method

Antibody-drug conjugates (ADCs) represent a rapidly evolving class of targeted therapies, with three distinct generations of conjugation methods. The first generation utilises lysine residues for drug attachment, while the second generation relies on cysteine coupling. The third generation, marks a significant advancement with site-specific conjugation, where cytotoxic drugs are attached at defined positions on the antibody, leading to a more homogeneous ADC with a precise drug-to-antibody ratio (DAR) of either 2 or 4. YMC Europe demonstrates the accurate DAR determination of a site-specific ADC using a YMC-Triart Bio C4 column, a robust wide-pore hybrid silica-based column designed to deliver reliable, high-resolution separations.